fda warning letters compounded semaglutide tirzepatide 2024 2025 Drugmakers battle pharmacies over compounded Ozempic and Zepbound : Shots

FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP-1 Drugs, and a Compounding Pharmacy Operating Without Control

25.72

★★★★☆4.8 (126)

September 2, 2025: U.S. compounding restrictions have stemmed a flood of compounded semaglutide and tirzepatide – Partnership for Safe Medicines

23.91

★★★★★4.9 (98)

Novo Nordisk calls out dangers of compounded GLP-1s in new ad

26.27

★★★★★5.0 (157)

Beyond the Headlines: FDA Warning Letters to GLP-1 Compounders

28.20

★★★★★4.7 (84)

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

20.70

★★★★★4.9 (203)

FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products

20.40

★★★★★5.0 (176)

The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP-1s, which are not FDA-approved and can pose risks to patients. FULL STORY:🔗https://tinyurl.com/3ztf9uj2

27.40

★★★★★4.8 (132)